England’s NHS is gearing up towards the ‘go live’ of a new digital transformation team that aims to drive service improvement using health data and technology.
Bristol-Myers Squibb and Concerto HealthAI, which specialises in using AI and machine learning technology to help generate ‘real world’ evidence (RWE) for trials, have announced a multi-yea
Doubts are mounting about whether Bristol-Myers Squibb’s $74 billion merger with Celgene will go ahead after another key investor came out against the deal.
Bristol-Myers Squibb’s (BMS) largest shareholder has come out against the company’s planned merger with Celgene, putting the future of the deal in doubt.
The FDA has started a speedy review of Merck KGaA and Pfizer’s new combination regimen for advanced kidney cancer, setting up a possible approval in June and piling more pressure on Bristol
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.